SLC5A2 and cardiovascular disorder: Key clinical recommendations include: SGLT2 inhibitors are recommended as first-line therapy in patients with T2DM and established cardiovascular disease (CVD) to reduce the risk of major adverse cardiovascular events (MACE) [2].